AIDS-related Kaposi Sarcoma

February 4, 2025 – Revium Rx (formerly Revium Recovery Inc., OTC: RVRC) has completed the strategic acquisition of LipoVation Ltd., an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. This acquisition marks a significant shift in Revium Rx’s focus toward nanoparticle-based therapeutics, positioning the company at the forefront of advanced drug delivery technologies for hard-to-treat diseases. LipoVation’s core technology was conceptualized by Prof. Yehezkel Barenholz, a world-renowned scientist and the inventor of Doxil, the first FDA-approved liposomal chemotherapy drug, widely used in the treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma. With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation. Revium Rx is developing a portfolio of advanced therapeutics, currently in the development stage, aimed at expanding the potential of existing treatments. Key programs include: A novel systemic formulation of a highly potent antibiotic, previously limited to topical use, designed to combat antibiotic-resistant bacterial infections. A cutting-edge adjuvant to enhance immune checkpoint inhibitors, improving the efficacy of cancer immunotherapies. An innovative approach to immunization, leveraging novel peptides and lipid-based technology for emerging infectious diseases. These next-generation encapsulated therapeutics are built on three core proprietary technologies: Clinically validated nanoparticles for targeted drug delivery. Advanced drug-loading and release systems to optimize bioavailability. Specialized lipid-based carriers for enhanced stability and controlled release. Following the acquisition, David Akunis has been appointed as Chief Executive Officer (CEO) of Revium Rx, bringing extensive managerial experience and financial expertise to drive the company’s new direction. With a strong background in fundraising and leadership, he is dedicated to advancing Revium Rx’s mission of developing innovative nanoparticle-based therapeutics and expanding the company’s impact in the pharmaceutical industry. Inna Martin, who has served as CEO since December 2020, has transitioned to Chief Operating Officer (COO) and President, focusing on product development and clinical trial preparation. This strategic shift ensures that Revium Rx progresses rapidly toward clinical-stage development while expanding strategic partnerships and accelerating growth. “As the demand for safer and more effective treatments continues to grow, our mission is to expand and enhance the therapeutic potential of existing treatments by utilizing proven drug delivery technologies to improve efficacy, safety, and clinical outcomes,” said David Akunis, CEO of Revium Rx. “Revium Rx's encapsulated therapeutics platform represents a transformative step forward in the fight against resistant infections, cancer, and emerging infectious diseases.” With this new strategic direction, Revium Rx continues to expand its research and development efforts, forging key partnerships and advancing its pipeline of highly potent therapeutics. The content above comes from the network. if any infringement, please contact us to modify.

On May 14, 2020, the Food and Drug Administration expanded the indication of pomalidomide (POMALYST, Celgene Corporation) to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative. Efficacy was investigated in Study 12-C-0047 , an open-label, single-arm clinical trial, conducted by the National Cancer Institute. Twenty-eight patients (18 HIV-positive, 10 HIV-negative) received 5 mg of pomalidomide orally once daily on days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity. All HIV-positive patients continued highly active antiretroviral therapy. The main efficacy outcome measure was overall response rate (ORR), which included complete response, clinical complete response, and partial response. Response was assessed by the investigator according to the AIDS Clinical Trial Group Oncology Committee response criteria for Kaposi sarcoma. Among the 18 HIV-positive patients, the ORR was 67% (95% CI: 41, 87) with a median response duration of 12.5 months (95% CI: 6.5, 24.9). Among the 10 HIV-negative patients, the ORR was 80% (95% CI: 44, 98) with a median response duration of 10.5 months (95% CI: 3.9, 24.2). The most common adverse reactions including laboratory abnormalities (≥ 30% of patients) who received pomalidomide were decreased absolute neutrophil count or white blood cells, elevated creatinine or glucose, rash, constipation, fatigue, decreased hemoglobin, platelets, phosphate, albumin, or calcium, increased ALT, nausea, and diarrhea. The recommended pomalidomide dose for Kaposi sarcoma is 5 mg once daily taken orally with or without food on days 1 through 21 of each 28‑day cycle until disease progression or unacceptable toxicity. Continue highly active antiretroviral therapy as HIV treatment in patients with AIDS-related Kaposi sarcoma. View full prescribing information for POMALYST. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Pomalidomide was granted priority review designation and breakthrough therapy designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter Content current as of: 05/15/2020 Regulated Product(s) Drugs Prescription Drugs 05/15/2020 Drugs Prescription Drugs Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

EAST WINDSOR, N.J., July 23, 2024 /PRNewswire/ -- ForDoz Pharma Corp., a private specialty pharmaceutical company focused on product development, manufacturing and commercialization of complex injectables, like liposomes, microspheres, nano-suspensions, etc., today announced the ANDA approval of DOXOrubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) from the United States Food and Drug Administration (US FDA). DOXOrubicin Hydrochloride Liposome Injection is indicated for the treatment of patients with ovarian cancer and AIDS-related Kaposi's sarcoma. Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma. "The approval of DOXOrubicin Hydrochloride Liposome Injection marks a major milestone for ForDoz Pharma as our 1st liposomal injectable pharmaceutical product to enter the US market. It will be distributed by Lupin Pharmaceuticals, Inc.," said James He, Founder and CEO of ForDoz Pharma. About ForDoz Pharma Corp. ForDoz Pharma Corporation is a privately-owned specialty pharmaceutical company focusing on development, manufacturing, and commercialization of value-added sterile and complex injectable products. Based on its proprietary technology platform and unique cGMP sterile manufacturing facility, the company's corporate strategy is to accelerate the development and manufacturing of complex injectables for its own and help others through CDMO service. Please visit for more information LinkedIn: Media Contact: James He, CEO 609-469-5949 SOURCE ForDoz Pharma Corp.